NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

NRG-GY012 will suspend to accrual effective 2/4/2019 due to a planned formal safety review as written in Statistical Section 13.7.3.The safety review allows for close monitoring in this population that may represent an older age range than previously studied and who may have undergone prior exposure to pelvic radiation. Safety and tolerability will be reviewed by the study team (Study Chair and co-chairs, Study statistician) and Developmental Therapeutics Chair before continuing accrual.

 

Once the review is complete, status as to re-activation will be broadcast.


 

Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address